Impact of Higher Insulin Prices on Out-of-Pocket Costs in Medicare Part D

Podobne zapisy

• Out-of-Pocket Costs for Novel Guideline-Directed Diabetes Therapies Under Medicare Part D
  od: DeJong, Colette, i wsp.
  Wydane: (2020)
• Out-of-Pocket Costs for Infliximab and Its Biosimilar for Rheumatoid Arthritis Under Medicare Part D
  od: Yazdany, Jinoos, i wsp.
  Wydane: (2018)
• Assessment of National Coverage and Out-of-Pocket Costs for Sacubitril/Valsartan Under Medicare Part D
  od: DeJong, Colette, i wsp.
  Wydane: (2019)
• Association of Out-of-Pocket Spending With Insulin Adherence in Medicare Part D
  od: Trish, Erin, i wsp.
  Wydane: (2021)
• Medicare Part D and Cost-Sharing for Antiretroviral Therapy and Preexposure Prophylaxis
  od: Tseng, Chien-Wen, i wsp.
  Wydane: (2020)